An interventional study of Digital nudge prompting in Readmission, Readmission Rates and Readmission, Hospital, sponsored by Yale University. Not yet recruiting at 1 site in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Yale University · Not applicable, Interventional, and Prevention
The PREVENT-R trial will evaluate an intervention targeting both clinician and patient behavior. The clinician-focused piece consists of an electronic medical record-based digital nudge presented to emergency department clinicians caring for eligible older adults at high risk of readmission. The nudge is intended to prompt clinicians to consider referral to the Service Navigator Program from the Agency on Aging of South Central Connecticut for patients with needs that may be addressed through community-based services and supports. The study will evaluate whether these mechanisms (clinician referral and patient program acceptance behavior) are associated with subsequent Emergency Department (ED) revisits and 30-day hospital re-admissions.
Yale University is the lead sponsor of 1,763 studies on the registry; 292 are open to participants now.
Of its 217 completed or terminated interventional studies of FDA-regulated products, 128 (59%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient Participants:
Clinician Participants:
Service Navigator Participants:
Exclusion Criteria:
Patient Participants:
The EMR will generate a digital nudge prompting the ED clinician to consider referral of the eligible patient to the SNP. Patients referred to the SNP will have the opportunity to engage with an SN and receive individualized navigation and support based on their identified needs.
Behavioral: Digital nudge prompting
No study-related EMR digital nudge will be generated. Clinicians will proceed with usual ED care and discharge practices, which may include referral to the SNP when clinically appropriate.
The EMR will generate a digital nudge prompting the treating ED clinician to consider referral of the patient to the SNP.
Percentage of participants with hospital readmissions
Hospital readmission within 30 days of the index ED visit.
Time frame: 30 days following the index ED
Percentage of participants referred to the SNP
Percentage of participants referred to the SNP to assess clinician referral behavior
Time frame: up to 3 months
Percentage of participants that accept or decline SNP services
Percentage of participants that accept or decline SNP services among those referred to and successfully contacted by the SNPt o assess patient acceptance
Time frame: up to 3 months
Post-SNP assessment
Patient-reported experience and outcomes will be assessed using the SNP survey administered at completion of SNP services. (This assessment is currently being refined.)
Time frame: up to 3 months
Percentage of participants that interact with SNs
Percentage of intervention arm participants that interact with SNs
Time frame: up to 3 months
Percentage of participants that utilize services
Percentage of intervention arm participants that utilized recommended services and supports.
Time frame: up to 3 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for May 2028, 18 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.